Serum Chitotriosidase Activity in Bronchopulmonary Dysplasia: A Cross-Sectional Study

Abstract

Objectives: Serum chitotriosidase (CHIT1) is a novel and promising biomarker of inflammatory diseases including airway and lung diseases. To date, there are no studies regarding serum CHIT1 activity in bronchopulmonary dysplasia (BPD) patients for determining inflammation. The aim of this study was to investigate whether serum CHIT1 activity is a useful marker for determining inflammation in BPD patients. Materials and Methods: In this cross-sectional study, demographic data and serum CHIT1 activity in patients with BPD (n=21) and in healthy controls (n=19) were compared. According to therapy, BPD patients were divided into two groups: inhaled steroid-free (n=13) and inhaled steroidpositive (n=8), and all the aforementioned data were compared between these two groups also. Results: In the comparison of laboratory parameters, no significant differences were in C-reactive protein (CRP), albumin and CRP/albumin ratio (CAR) between healthy group and BPD group. While higher CHIT1 activity was detected in BPD group [16.4±13.0 nmol/mL/h] compared to healthy group [12.1±8.3 nmol/mL/h], this difference was not statistically significant. (p=0.456). On the other hand, CHIT1 activity was significantly higher in inhaled steroid-free BPD patients (p=0.025) than inhaled steroid-positive ones. There was a positive correlation between ages and serum CHIT1 (r=0.26, p=0.025) in all subjects. On the other hand, in the correlation analysis of laboratory parameters, there was no correlation between CHIT1 level and CRP, albumin and CAR in all subjects. Conclusion: Although this study provided some evidence that inhaled steroid treatment might decrease serum CHIT1 activity in BPD, further studies with more patients are necessary.

Keywords

• Bronchopulmonary Dysplasia
• Chitotriosidase Activity
• Inflammation

Bronkopulmoner Displazide Serum Kitotriozidaz Aktivitesi: Kesitsel Bir Çalışma

Abstract

Amaç: Serum kitotriozidaz (CHIT1), hava yolu ve akciğer hastalıkları dahil olmak üzere enflamatuvar hastalıklarda kullanılan yeni bir biyobelirteçtir. Bugüne kadar, bronkopulmoner displazi (BPD) hastalarında enflamasyonu belirlemek için serum CHIT1 aktivitesini değerlendiren bir çalışma yoktur. Bu çalışmanın amacı, serum CHIT1 aktivitesinin BPD hastalarında enflamasyonu belirlemede yararlı bir belirteç olup olmadığını araştırmaktır. Gereç ve Yöntem: Bu kesitsel çalışmada, BPD’li hastalarda (n=21) ve sağlıklı kontrollerde (n=19) demografik veriler ve serum CHIT1 aktivitesi karşılaştırıldı. Tedaviye göre BPD hastaları inhale steroid tedavisi almayan (n=13) ve inhale steroid tedavisi alan (n=8) olmak üzere iki gruba ayrıldı ve yukarıda belirtilen tüm veriler bu iki grup arasında da karşılaştırıldı. Bulgular: Laboratuvar parametrelerinin karşılaştırılmasında, sağlıklı grup ile BPD grubu arasında C-reaktif protein (CRP), albümin ve CRP/albümin oranı (CAO) açısından anlamlı fark bulunmadı. BPD grubunda [16,4±13,0 nmol/mL/h] sağlıklı gruba [12,1±8,3 nmol/mL/h] göre daha yüksek CHIT1 aktivitesi saptanırken, bu fark istatistiksel olarak anlamlı değildi (p=0,456). Öte yandan, inhale steroid içermeyen BPD hastalarında CHIT1 aktivitesi inhale steroid tedavisi alanlara göre anlamlı olarak daha yüksekti (p=0,025). Tüm çalışma popülasyonunda yaş ile serum CHIT1 (r=0,26, p=0,025) arasında pozitif bir korelasyon vardı. Öte yandan laboratuvar parametrelerinin korelasyon analizinde tüm çalışma popülasyonunda CHIT1 düzeyi ile CRP, albümin ve CAO arasında anlamlı bir ilişki yoktu. Sonuç: Bu çalışma, inhale steroid tedavisinin BPD’de serum CHIT1 aktivitesini azaltabileceğine dair bazı kanıtlar sağlasa da, daha fazla hasta içeren ileri çalışmalara ihtiyaç vardır.

Keywords

• Bronkopulmoner Displazi
• Kitotriozidaz Aktivitesi
• enflamasyon

References

1. 1. Araujo AC, Souto-Padrón T, de Souza W. Cytochemical localization of carbohydrate residues in microfilariae of Wuchereria bancrofti and Brugia malayi. J Histochem Cytochem. 1993;41:571-578.
2. 2. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol. 1994;48:471-497.
3. 3. Shahabuddin M, Kaslow DC. Plasmodium: parasite chitinase and its role in malaria transmission. Exp Parasitol. 1994;79:85-88.
4. 4. Burton OT, Zaccone P. The potential role of chitin in allergic reactions. Trends Immunol. 2007;28:419-422.
5. 5. Funkhouser JD, Aronson NN Jr. Chitinase family GH18: evolutionary insights from the genomic history of a diverse protein family. BMC Evol Biol. 2007;7:96.
6. 6. Boot RG, Blommaart EF, Swart E, et al. Identification of a novel acidic mammalian chitinase distinct from chitotriosidase. J Biol Chem. 2001;276:6770-6778.
7. 7. Di Rosa M, Musumeci M, Scuto A, et al. Effect of interferon-gamma, interleukin-10, lipopolysaccharide and tumor necrosis factor-alpha on chitotriosidase synthesis in human macrophages. Clin Chem Lab Med. 2005;43:499-502.
8. 8. van Eijk M, van Roomen CP, Renkema GH, et al. Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int Immunol. 2005;17:1505-1512.

9. 9. Kzhyshkowska J, Gratchev A, Goerdt S. Human chitinases and chitinaselike proteins as indicators for inflammation and cancer. Biomark Insights. 2007;2:128-146.
10. 10. Malaguarnera L, Di Rosa M, Zambito AM, et al. Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. Gut. 2006;55:1313-1320.
11. 11. Fantino E, Gangell CL, Hartl D, Sly PD; AREST CF. Airway, but not serum or urinary, levels of YKL-40 reflect inflammation in early cystic fibrosis lung disease. BMC Pulm Med. 2014;14:28.
12. 12. Leonardi S, Parisi GF, Capizzi A, Manti S, et al. YKL-40 as marker of severe lung disease in cystic fibrosis patients. J Cyst Fibros. 2016;15:583-586.
13. 13. Mack I, Hector A, Ballbach M, et al. The role of chitin, chitinases, and chitinase-like proteins in pediatric lung diseases. Mol Cell Pediatr. 2015;2:3.
14. 14. Olgun Yazar H, Yazar T, Özdemir S, et al. Serum C-reactive protein/albumin ratio and restless legs syndrome. Sleep Med. 2019;58:61-65.
15. 15. Qin G, Tu J, Liu L, et al. Serum Albumin and C-Reactive Protein/Albumin Ratio Are Useful Biomarkers of Crohn’s Disease Activity. Med Sci Monit. 2016;22:4393-4400.
16. 16. Llop-Talaveron J, Badia-Tahull MB, Leiva-Badosa E. An inflammationbased prognostic score, the C-reactive protein/albumin ratio predicts the morbidity and mortality of patients on parenteral nutrition. Clin Nutr. 2018;37:1575-1583.
17. 17. Hollak CE, van Weely S, van Oers MH, et al. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 1994;93:1288-1292.
18. 18. Young E, Chatterton C, Vellodi A, et al. Plasma chitotriosidase activity in Gaucher disease patients who have been treated either by bone marrow transplantation or by enzyme replacement therapy with alglucerase. J Inherit Metab Dis. 1997;20:595-602.
19. 19. Hector A, Kormann MS, Mack I, et al. The chitinase-like protein YKL-40 modulates cystic fibrosis lung disease. PLoS One. 2011;6:e24399.
20. 20. Seibold MA, Donnelly S, Solon M, et al. Chitotriosidase is the primary active chitinase in the human lung and is modulated by genotype and smoking habit. J Allergy Clin Immunol. 2008;122:944-950.e3.
21. 21. Létuvé S, Kozhich A, Humbles A, et al. Lung chitinolytic activity and chitotriosidase are elevated in chronic obstructive pulmonary disease and contribute to lung inflammation. Am J Pathol. 2010;176:638-649.
22. 22. Bargagli E, Olivieri C, Margollicci M, et al. Serum chitotriosidase levels in patients with allergic and non-allergic asthma. Respiration. 2010;79:437-438.
23. 23. Boot RG, Renkema GH, Verhoek M, et al. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem. 1998;273:25680-25685.
24. 24. James AJ, Reinius LE, Verhoek M, et al. Increased YKL-40 and Chitotriosidase in Asthma and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2016;193:131-142.
25. 25. Bennett D, Cameli P, Lanzarone N, et al. Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis. Respir Res. 2020;21:6.